Portal de Periódicos da CAPES

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

2014; Elsevier BV; Volume: 125; Issue: 6 Linguagem: Inglês

10.1182/blood-2014-07-590315

1528-0020

David T Yeung, Michael Osborn, Deborah L. White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher Arthur, Yiu Lam Kwan, Judith Trotman, Cecily Forsyth, John Taper, David M. Ross, J. Beresford, Constantine S. Tam, Anthony K. Mills, Andrew Grigg, Timothy P. Hughes,

Acute Lymphoblastic Leukemia research

Key Points Using imatinib to treat CML first-line, with selective nilotinib switching, leads to excellent molecular response and survival. This strategy may be preferable to universal first-line use of more potent agents, considering efficacy, toxicity, and economic factors.